Browsing Centre for Preventative Neurology by Title
Now showing items 21-40 of 132
-
COVID-19 vaccine response in people with multiple sclerosis
The purpose of this study was to investigate the effect of disease modifying therapies on immune response to severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccines in people with multiple sclerosis (MS). -
Current Review and Next Steps for Artificial intelligence in Multiple Sclerosis risk research
(Elsevier, 2021-03)In the last few decades, the prevalence of multiple sclerosis (MS), a chronic inflammatory disease of the nervous system, has increased, particularly in Northern European countries, the United States, and United Kingdom. ... -
Demyelinating Events Following Initiation of Anti-TNFα Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis.
(2021-04-16)OBJECTIVE: To establish the incidence of demyelination in patients who have received anti-tumor necrosis factor alpha (anti-TNFα) therapy, through analysis of adverse events reported in a prospective cohort of patients ... -
Differences in the Presentation and Progression of Parkinson's Disease by Sex
(Wiley, 2020-10-01) -
Differing Impact of DMT on Relapse and Progression: Time to Consider Inflammation and Neuroprotection Separately?
The artificial distinction between relapsing remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS) can lead to substantial difficulties in decisions on disease-modifying therapy (DMT) at ... -
Digesting science: Developing educational activities about multiple sclerosis, prevention and treatment to increase the confidence of affected families.
(2020-11-13)BACKGROUND: The majority of information sources for children of people with multiple sclerosis (MS) are paper, or text, based and require high levels of literacy. OBJECTIVE: To develop educational activities to inform ... -
Domotics, smart homes and Parkinson’s disease
(IOS Press, 2021-02-19) -
Embedding Patient Input in Outcome Measures for Long-Term Disease-Modifying Parkinson Disease Trials.
(2023-12-22)BACKGROUND: Clinical trials of disease-modifying therapies in PD require valid and responsive primary outcome measures that are relevant to patients. OBJECTIVES: The objective is to select a patient-centered primary outcome ...